ArticleJACC. Case reports2026
Puberty-Associated Emergence of Hypertrophic Cardiomyopathy: When Genetics Meets Growth.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertrophic cardiomyopathy (HCM) is a genetically heterogeneous disease with variable and incomplete penetrance, with phenotypic expression occurring across developmental stages, potentially influenced by hormonal and other biological modifiers. Genotype-positive individuals may remain phenotype-negative during childhood, with phenotypic expression emerging during adolescence or early adulthood. Factors influencing the timing of phenotypic conversion remain incompletely understood. CASE SUMMARY: A 13-year-old asymptomatic boy with a strong family history of hypertrophic obstructive cardiomyopathy underwent routine cardiology follow-up. Previous cardiac evaluation at age 9 demonstrated normal electrocardiographic and echocardiographic results. At age 13, coinciding with pubertal development, new-onset asymmetric septal hypertrophy with systolic anterior motion and left ventricular outflow tract obstruction was identified on echocardiography. Cardiac magnetic resonance confirmed significant septal hypertrophy. Subsequent genetic testing confirmed that the patient had a pathogenic MYH7 variant. DISCUSSION: This case illustrates the dynamic penetrance of MYH7-related HCM and highlights adolescence as a potential window for phenotypic emergence, possibly influenced by pubertal hormonal changes. Pubertal growth and associated physiological changes may further modulate disease expression in genetically predisposed individuals. These findings underscore the importance of continued longitudinal surveillance throughout childhood, particularly during periods of rapid somatic growth. TAKE-HOME MESSAGES: Phenotypic expression of HCM in MYH7 mutation carriers may emerge during periods of somatic growth and hormonal developmental transition. Periods of rapid somatic growth, such as puberty, may represent a critical window for phenotypic evolution, highlighting the importance of repeated and more frequent cardiac screening especially around growth spurts in genotype-positive individuals. Risk stratification and recommendations regarding sports participation in pediatric HCM should be individualized and based on clinical findings, genetic status, and shared decision-making rather than universal restriction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.